Neurological manifestations in Wilson’s disease –possible treatment options for symptoms

References

• European Association For The Study of The Liver Disease. EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671–685.
   PubMed Web of Science ®Google Scholar
• Roberts E, Schilsky M. Diagnosis and treatment of Wilson’s disease an update. Hepatology. 2008;47(6):2089–2111.
   PubMed Web of Science ®Google Scholar
• Dusek P, Litwin T, Czlonkowska A. Wilson disease and other neurodegenerations with metal accumulations. Neurol Clin. 2015;33(1):175–204.
   PubMed Web of Science ®Google Scholar
• Aggarval A, Bhatt M. The pragmatic treatment of Wilson’s disease. Mov Disord Clin Pract. 2014;1:14–23.
   Google Scholar
• Beinhardt S, Leiss W, Stattermayer AF, et al. Long term outcomes of patients with Wilson disease in large Austrian cohort. Clin Gastroenetrol Hepatol. 2014;12(4):683–689.
   PubMed Web of Science ®Google Scholar
• Brewer G, Fink J, Hedera P. Diagnosis and treatment of Wilson’s disease. Semin Neurol. 1999;19(3):261–269.
   PubMed Web of Science ®Google Scholar
• Bruha R, Marecek Z, Pospilova L, et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int. 2011;31(1):83–91.
   PubMed Web of Science ®Google Scholar
• Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson’s disease with d-penicillamine and zinc sulphate. J Neurol. 1996;243(3):269–273.
   PubMed Web of Science ®Google Scholar
• Czlonkowska A, Tarnacka B, Litwin T, et al. Wilson’s disease cause of mortality in 164 patients during 1992-2003 observation period. J Neurol. 2005;252(6):698–703.
   PubMed Web of Science ®Google Scholar
• Członkowska A, Litwin T, Karliński M, et al. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol. 2014;21(4):599–606.
   PubMed Web of Science ®Google Scholar
• Bakheit AMO. Management of neurogenic dysphagia. Postgrad Med J. 2001;77(913):694–699.
   PubMed Web of Science ®Google Scholar
• Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilson’s disease. Ann N Y Sci. 2014;1315:81–85.
   PubMed Web of Science ®Google Scholar
• Chou KL, Evatt M, Hinson V, et al. Sialorrhea in Parkinson’s disease: a review. Mov Disord. 2007;22(16):2306–2313.
   PubMed Web of Science ®Google Scholar
• Crary MA, Carnaby-Mann GD, Faunce A. Electrical stimulation therapy for dysphagia: descriptive results of two surveys. Dysphagia. 2007;22(3):165–173.
   PubMed Web of Science ®Google Scholar
• Dwarakanath S, Zafar A, Yadav R, et al. Does lesioning surgery have role in the management of multietiological tremor in the era of deep brain stimulation? Clin Neurol Neurosurg. 2014;125:131–136.
   PubMed Web of Science ®Google Scholar
• Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014;11(1):153–160.
   PubMed Web of Science ®Google Scholar
• Gage H, Storey L. Rehabilitation for Parkinson’s disease: a systematic review of available evidence. Clin Rehabil. 2004;18(5):463–482.
   PubMed Web of Science ®Google Scholar
• Goodwin VA, Richards SH, Taylor RS, et al. The effectivemess of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2008;23(5):631–640.
   PubMed Web of Science ®Google Scholar
• Lal D, Hotaling AJ. Drooling. Curr Opin in Otolaryngol Head Neck Surg. 2006;14(6):381–386.
   PubMedGoogle Scholar
• Loser C, Aschl G, Hebuterne X, et al. ESPEN guidelines on artificial enteral nutrition – percutaneous endoscopic gastrostomy (PEG). Clin Nutr. 2005;24(5):848–861.
   PubMed Web of Science ®Google Scholar
• Puschmann A, Wszolek ZK. Diagnosis and treatment of common forms of tremor. Semin Neurol. 2011;31(1):65–77.
   PubMed Web of Science ®Google Scholar
• Schneider SA, Deuschl G. The treatment of tremor. Neurotherapeutics. 2014;11(1):128–138.
   PubMed Web of Science ®Google Scholar
• Teive HA, Munhoz RP, Souza MM, et al. Status dystonicus study of five cases. Arq Neuropsiquiatr. 2005;63(1):26–29.
   PubMed Web of Science ®Google Scholar
• Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11(1):139–152.
   PubMed Web of Science ®Google Scholar
• Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia. 1988;3(2):73–78.
   PubMedGoogle Scholar
• Woitalla D, Goetze O. Treatment approaches of gastrointestinal dysfunction in Parkinson’s disease, therapeutical options and future perspectives. J Neurol Sci. 2011;310(1–2):152–158.
   PubMed Web of Science ®Google Scholar
• Lorincz MT. Neurologic Wilson’s disease. Ann N Y Sci. 2010;1184:173–187.
   PubMed Web of Science ®Google Scholar
• Svetel M, Kozic D, Stefanova E, et al. Dystonia in Wilson’s disease. Mov Disord. 2001;16(4):719–723.
   PubMed Web of Science ®Google Scholar
• Trocello JM, Osmani K, Pernon M, et al. Hypersialorrhea in Wilson’s disease. Dysphagia. 2015;30(5):489–495.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Aggarwal N, Nagral A, et al. A novel global assessment scale for Wilson’s diseases (GAS for WD). Mov Disord. 2009;24(4):509–518.
   PubMed Web of Science ®Google Scholar
• Czlonkowska A, Tarnacka B, Moller JC, et al. Unified Wilson’s diseases rating scale - proposal for the neurological scoring of Wilson’s diseases patients. Neurol Neurochir Pol. 2007;41(1):1–12.
   PubMed Web of Science ®Google Scholar
• Holscher S, Leinweber B, Hefter H, et al. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease. Eur Neurol. 2010;64(2):83–87.
   PubMed Web of Science ®Google Scholar
• Chakor RT, Bharote H, Eklare N, et al. Unilateral rubral tremors in Wilson’s disease treated with dimercaprol. Ann Indian Acad Neurol. 2015;18(1):115–116.
   PubMed Web of Science ®Google Scholar
• Pal PK, Sinha S, Pillai S, et al. Successful treatment of tremor in Wilson’s disease by thalamotomy: A case report. Mov Disord. 2007;22(15):2287–2290.
   PubMed Web of Science ®Google Scholar
• Paliwal VK, Gupta PK, Pradhan S. Gabapentin as a rescue drug inD-penicillamine-induced status dystonicus in patients with Wilson disease. Neurol India. 2010;58(5):761–763.
   PubMed Web of Science ®Google Scholar
• Burke JF, Dayalu P, Nan B, et al. Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism Relat Disord. 2011;17(7):551–556.
   PubMed Web of Science ®Google Scholar
• Teive HA, Kluppel LE, Munhoz RP, et al. Jaw-opening oromandibular dystonia secondary to Wilson’s disease treated with botulinum toxin type A. Arq Neuropsiquiatr. 2012;70(6):407–409.
   PubMed Web of Science ®Google Scholar
• Litwin T, Chabik G, Czlonkowska A. Acute focal dystonia induced by tricyclic antidepressant in a patient with Wilson disease: a case report. Neurol Neurochir Pol. 2013;47(5):502–506.
   PubMed Web of Science ®Google Scholar
• Litwin T, Gromadzka G, Czlonkowska A. Neurological presentation of Wilson’s disease in a patient after liver transplantation. Mov Disord. 2008;23(5):743–745.
   PubMed Web of Science ®Google Scholar
• Barbeau A, Friesen H. Treatment of Wilson’s disease with L-dopa after failure with penicillamine. Lancet. 1970;1(7657):1180–1182.
   PubMed Web of Science ®Google Scholar
• Gelmers HJ, Troost J, Willemse J. Wilson’s disease: modification by L-DOPA. Neuropadiatrie. 1973;4(4):453–457.
   PubMedGoogle Scholar
• Gondim FA, Araujo DF, Oliveira IS, et al. Levodopa-responsive Parkinsonism and small fiber dysfunction in patients with Wilson’s disease. Move. 2013;28:S351–S2.
   Google Scholar
• Berio A, Vento R, Di Stefano A. Favorable results with an association of L-dopa and amantadine added to penicillamine in the treatment of Wilson’s disease. Minerva Pediatr. 1973;25(18):807–813.
   PubMedGoogle Scholar
• Frankel JP, Hughes A, Lees AJ, et al. Use of apomorphine to test for dopamine responsiveness in Wilson’s disease. Lancet. 1989;2(8666):801–802.
   PubMed Web of Science ®Google Scholar
• Morgan JP, Preziosi TJ, Bianchine JR. Ineffectiveness of L-dopa as supplement to penicillamine in a case of Wilson’s disease. Lancet. 1970;2(7674):659.
   PubMed Web of Science ®Google Scholar
• Micheli F, Tschopp L, Cerosimo MG. Oxcarbamazepine-responsive paroxysmal kinesigenic dyskinesia in Wilson disease. Clin Neuropharm. 2011;34(6):262–264.
   PubMed Web of Science ®Google Scholar
• Hirabayashi S, Kanda H, Tsuno T, et al. Effects of high-dosage trihexyphenidyl on symptomatic dystonia in a case of Wilson disease. No To Hattatsu. 1985;17(6):571–576.
   PubMedGoogle Scholar
• Sidiropoulos C, Hutchison W, Mestre T, et al. Bilateral pallidal stimulation for Wilson’s disease. Mov Disord. 2013;28(9):1292–1295.
   PubMed Web of Science ®Google Scholar
• Hedera P. Treatment of Wilson’s disease motor complications with deep brain stimulation. Ann N Y Acad Sci. 2014;1315:16–23.
   PubMed Web of Science ®Google Scholar
• Barthel H, Hermann W, Kluge R, et al. Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. Am J Neuroradiol. 2003;23:234–238.
   Google Scholar
• Litwin T, Gromadzka G, Samochowiec J, et al. Association of dopamine receptor gene polymorphisms with the clinical course of Wilson disease. JIMD Rep. 2013;8:73–80.
   PubMedGoogle Scholar
• Litwin T, Dzieżyc K, Karliński M, et al. Early neurological worsening in patients with Wilson’s Diseases. J Neurol Sci. 2015;355(1–2):162–167.
   PubMed Web of Science ®Google Scholar
• Hamada Y. Objective data assessment (ODA) methods as nutritional assessments tools. J Med Invest. 2015;62(3–4):119–122.
   PubMedGoogle Scholar
• Lee SY, Yang HE, Yang HS, et al. Neuromuscular electrical stimulation therapy for dysphagia caused by Wilson’s disease. Ann Rehabil Med. 2012;36(3):409–413.
   PubMedGoogle Scholar
• Da Silva-Junor FP, Carrasco AEAB, DaSilva Mendes AM, et al. Swallowing dysfunction in Wilson’s disease: a scintigraphic study. Neurogstroenterol Motil. 2008;20(4):285–290.
   PubMed Web of Science ®Google Scholar
• Berry WR, Darley FL, Aronson AE. Dysarthria in Wilson’s disease. J Speech Hear Res. 1974;17(2):169–183.
   PubMedGoogle Scholar
• Walshe JM, Yealland M. Wilson’s disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry. 1992;55(8):692–696.
   PubMed Web of Science ®Google Scholar
• Friedman A, Potulska A. Quantitative assessment of parkinsonian silorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord. 2001;7(4):329–332.
   PubMed Web of Science ®Google Scholar
• Bax M. Drooling. Dev Med Child Neurol. 1992;34(10):847–848.
   PubMed Web of Science ®Google Scholar
• Dusek P, Roos PM, Litwin T, et al. The neurotoxicity of iron, copper, and manganese in Parkinson’s and Wilson’s disease. J Trace Elem Med Biol. 2015;31:193–203.
   PubMed Web of Science ®Google Scholar
• Denning TR, Berrios GE, Walshe JM. Wilson’s disease and epilepsy. Brain. 1988;111:1139–1155.
   PubMed Web of Science ®Google Scholar
• Pestana Knight EM, Gilman S, Selwa L. Status epilepticus in Wilson’s disease. Epileptic Disord. 2009;11:138–143.
   PubMed Web of Science ®Google Scholar
• Prashanth LK, Sinha S, Taly AB, et al. Spectrum of epilepsy in Wilson’s disease with electroencephalographic, MR imaging and pathological correlates. J Neurol Sci. 2010;291(1–2):44–51.
   PubMed Web of Science ®Google Scholar
• Barbosa ER, Silveira-Moriyama L, Costa Machado A, et al. Wilson’s disease with myoclonus and white matter lesions. Parkinsonism Relat Disord. 2007;13(3):185–188.
   PubMed Web of Science ®Google Scholar
• Benbir G, Gunduz A, Ertan S, et al. Partial status epilepticus induced by hypocupremia in a patient with Wilson’s disease. Seizure. 2010;19(9):602–604.
   PubMed Web of Science ®Google Scholar
• Asconape JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol. 2014;119:417–432.
   PubMedGoogle Scholar
• Medici V, Mirante VG, Fassati LR, et al. Liver transplantation for Wilson’s disease: the burden of neurological and psychiatric disorders. Liver Transpl. 2005;11(9):1056–1063.
   PubMed Web of Science ®Google Scholar
• Wang XH, Cheng F, Zhang F, et al. Living related liver transplantation for Wilson’s disease. Transplant Proc. 2001;18(6):651–656.
   Google Scholar
• Weiss KH, Schaefer M, Gotthardt DN, et al. Outcome and development of symptoms after orthopic liver transplantation for Wilson disease. Clin Transplant. 2013;27(6):914–922.
   PubMed Web of Science ®Google Scholar
• Guillaud O, Dumortier J, Sobesky R, et al. Long term results of liver transplantation for Wilson’s disease: experience in France. J Hepatol. 2014;60(3):579–589.
   PubMed Web of Science ®Google Scholar
• Catana AM, Medici V. Liver transplantation for Wilson’s disease. World J Hepatol. 2012;4(1):5–10.
   PubMedGoogle Scholar
• Stracciari A, Tempestini A, Borghi A, et al. Effect of liver transplantation on neurological manifestations in Wilson’s disease. Arch Neurol. 2000;57(3):384–386.
   PubMedGoogle Scholar
• Litwin T, Dziezyc K, Poniatowska R, et al. Effect of liver transplantation on brain magnetic resonance imaging pathology in Wilson disease: a case report. Neurol Neurochir Pol. 2013;47(4):393–397.
   PubMed Web of Science ®Google Scholar
• Yagci MA, Tardu A, Karagul S, et al. Influence of liver transplantation on neuropsychiatric manifestations of Wilson disease. Transplant Proc. 2015;47(5):1469–1473.
   PubMed Web of Science ®Google Scholar
• Geissler I, Heinemann K, Rohm S, et al. Liver transplantation for hepatic and neurological Wilson’s disease. Transplant Proc. 2003;35(4):1445–1446.
   PubMed Web of Science ®Google Scholar
• Bax RT, Hassler A, Luck W, et al. Cerebral manifestation of Wilson’s disease successfully treated with liver transplantation. Neurology. 1998;51(3):863–865.
   PubMed Web of Science ®Google Scholar
• Marin C, Robles R, Parilla G, et al. Liver transplantation in Wilson’s disease: are its indications established? Transplant Proc. 2007;39:2300–2301.
   PubMed Web of Science ®Google Scholar
• Chen CL, Chen YS, Lui CC, et al. Neurological improvement of Wilson’s disease after liver transplantation. Transplant Proc. 1997;29:497–498.
   PubMed Web of Science ®Google Scholar
• Robles R, Parilla P, Sicilia J, et al. Indications and results of liver transplants in Wilson’s disease. Transplant Proc. 1999;31:2453–2454.
   PubMed Web of Science ®Google Scholar
• Weiss KH, Gothardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson’s disease. Gastroenterology. 2011;140(4):1189–1198.
   PubMed Web of Science ®Google Scholar